AstraZeneca Pauses £200 Million Cambridge Investment, Raising Concerns for UK Pharma Industry

Photo:Getty images
AstraZeneca, one of the world’s largest pharmaceutical companies, has announced that it is pausing its planned £200 million investment in a research facility in Cambridge, UK. The project, first announced in March 2024, was expected to create around 1,000 jobs and expand the company’s existing Discovery Centre, which already employs 2,300 researchers and scientists. The pause marks another setback for the UK life sciences sector, which has faced challenges in attracting large-scale investments from global pharmaceutical companies.

The decision comes after similar moves by other major firms. Earlier this year, US-based Merck scrapped a £1 billion expansion plan in the UK, citing limited government support. AstraZeneca itself also halted a £450 million investment to expand a vaccine manufacturing plant in Merseyside earlier in 2025, pointing to reductions in government backing as a key factor.

An AstraZeneca spokesperson said, “We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused.” This follows the company’s announcement in July that it would invest $50 billion (£36.9 billion) in the United States to strengthen medicines manufacturing and research. The move highlights the growing trend of pharmaceutical companies prioritizing the US over the UK due to government incentives, favorable policies, and market conditions.

Over the last decade, UK spending on medicines has declined from 15% of the National Health Service (NHS) budget to just 9%, while most developed countries continue to spend between 14% and 20% of their healthcare budgets on medicines. Analysts suggest this reduction, along with uncertainties over government support, has made the UK less attractive for high-value pharmaceutical investments.

The paused Cambridge project was intended to enhance AstraZeneca’s existing Discovery Centre, a hub for innovative research in medicine and science. It was part of the last government’s promise of £650 million investment in the UK life sciences sector, none of which is now guaranteed to go ahead. Former UK Chancellor Jeremy Hunt had previously emphasized that life sciences are “crucial for the country’s health, wealth, and resilience,” while current Chancellor Rachel Reeves called AstraZeneca one of the nation’s “great companies.”

AstraZeneca’s CEO, Pascal Soriot, has defended the company’s global investment strategy, noting that investing in the US allows the company to take advantage of better government incentives and larger markets. With mounting pressure from former US President Donald Trump, who has encouraged pharmaceutical companies to expand in the US, the trend is likely to continue.

The pause of the Cambridge project raises concerns about job creation and innovation in the UK. Thousands of highly skilled researchers and scientists who might have benefited from the expansion could face fewer opportunities locally. Experts say that without strong government support, including funding and clear policies, the UK may struggle to compete with the US and other countries in attracting large-scale pharmaceutical projects.

This development is a reminder of the complex balance between government policy, corporate investment, and global competition. While the UK continues to promote life sciences as a priority industry, companies like AstraZeneca are weighing the benefits of investing abroad where incentives, market size, and policy support are stronger.

In conclusion, AstraZeneca’s decision to pause its £200 million Cambridge expansion underscores the need for the UK government to revisit its strategy for supporting high-value pharmaceutical investments. Without timely action, the country risks losing its position as a leader in medical research and innovation, along with thousands of potential jobs that could drive both the economy and public health forward.